Provider Newsflash
August 2024

FDA Recall – Baxter International

Purpose of this communication:

- We are writing to inform you that effective immediately the FDA has issued notice of a voluntary recall by Baxter International, Inc. of Lot number N008235 Heparin Sodium in 0.9% Sodium Chloride Injection, Expiration date August 31, 2024 which was distributed between March 12, 2023 and August 24, 2023. The recall is due to the potential for elevated endotoxin levels based on issues related to the bacterial endotoxin test specific to this lot number. Use of heparin with higher than acceptable endotoxin levels may lead to significant adverse health consequences.

What do I need to do?

- Please review the following recall notice: Baxter Issues Voluntary Nationwide Recall of One Lot of Heparin Sodium 0.9% Sodium Chloride Injection Due to Potential for Elevated Endotoxin Levels | FDA
- Notify impacted patients and facilitate the replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.

EDRC# 1604. 092021